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mortality, but not stroke, in patients with
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http://dx.doi.org/10.1016/j.ahj.2016.12.008Atrial fibrillation (AF) increases the risk of stroke,
systemic embolism, and death.1,2 Oral anticoagulants
(OACs) reduce the risk of these outcomes but also increase
the risk of bleeding.3,4 Balancing the clinical benefit for
stroke prevention with bleeding is therefore critical.
Anemia is common in patients with AF and may reflect
occult bleeding. Indeed, anemia has been identified as a
strong predictor of bleeding in anticoagulated patients
with AF.5-11 Anemia also has multiple etiologies unrelated
to bleeding and has been associated with an increased
incidence of thromboembolic events in several popula-
tions,12-15 including patients with AF.16
We hypothesized that anemia is an important comor-
bidity in patients with AF that is strongly associated with
bleeding and stroke and that apixaban will have similar
Table I. Baseline characteristics according to the presence or absence of anemia
Characteristic Anemia⁎ (n = 2288) No anemia (n = 15,815) P
Age, median (25th-75th), y 73 (67-79) 69 (62-76) b.0001
Female sex, no. (%) 803 (35.1%) 5578 (35.3%) .8705
Systolic BP, median (25th-75th), mm Hg 130 (119-140) 130 (120-140) b.0001
Heart rate, median (25th-75th), beats/min 74 (64-84) 76 (66-85) b.0001
Weight, median (25th-75th), kg 78 (65-92) 83 (70-96) b.0001
Region, n (%) b.0001
North America 736 (32.2) 3713 (23.5)
Latin America 323 (14.1) 3114 (19.7)
Europe 800 (35.0) 6523 (41.2)
CHADS2 score, mean (SD) 2.4 (1.16) 2.1 (1.09) b.0001
HAS-BLED score, mean (SD) 2.0 (1.03) 1.7 (1.05) b.0001
Medical history, n (%)
Prior stroke or SE 505 (22.1) 3013 (19.1) .0006
Prior bleeding event 461 (20.1) 2565 (16.2) b.0001
History of anemia 542 (23.7) 696 (4.4) b.0001
Hypertension 2017 (88.2) 13,821 (87.4) .3020
Diabetes 772 (33.7) 3755 (23.7) b.0001
HF 917 (40.1) 5497 (34.8) b.0001
CAD 931 (40.7) 5084 (32.2) b.0001
Renal dysfunction (eGFR b50 mL/min) 737 (32.3) 2260 (14.3) b.0001
Type of AF .0163
Paroxysmal 390 (17.0) 2389 (15.1)
Persistent or permanent 1898 (83.0) 13,423 (84.9)
Medications at randomization, n (%)
Prior use of VKAs† 1334 (58.3) 9016 (57.0) .2420
Aspirin 775 (33.9) 4832 (30.6) .0013
Clopidogrel 82 (3.6) 254 (1.6) b.0001
Amiodarone 290 (12.9) 1749 (11.2) .0223
β-Blocker 1430 (63.5) 9997 (64.2) .4982
Digoxin 696 (30.9) 5098 (32.8) .0800
Calcium blocker 741 (32.9) 4801 (30.8) .0487
Statin 1090 (48.4) 6344 (40.8) b.0001
NSAID 245 (10.9) 1268 (8.1) b.0001
Gastric antacid drugs 648 (28.8) 2683 (17.2) b.0001
P value compares patients with anemia versus no anemia. BP, Blood pressure; SE, systemic embolism; HF, heart failure; CAD, coronary artery disease; eGFR, estimated glomerular
filtration rate; VKA, vitamin K antagonist; NSAID, nonsteroidal anti-inflammatory drug.
⁎Anemia at baseline defined as Hb b13.0 in men and Hb b12.0 g/dL in women.
†Prior use of vitamin K antagonists for N30 consecutive days.
Westenbrink et al 141
American Heart Journal
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hypotheses, we retrospectively analyzed the Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial that
included 18,201 patients with AF randomized to
dose-adjusted warfarin (target international normalized
ratio [INR], 2.0-3.0) or apixaban 5 mg twice daily.17Methods
ARISTOTLE trial design
The ARISTOTLE trial design and the results of the main
study have been published previously.17,18 Briefly, the
primary objective of the ARISTOTLE trial was to establish
the noninferiority of apixaban 5 mg twice daily compared
with warfarin (target INR, 2.0-3.0) for the prevention of
stroke or systemic embolism in patients with AF. TheARISTOTLE investigators randomized 18,201 patients
with AF and at least 1 additional risk factor for stroke to
receive apixaban 5 mg twice daily or dose-adjusted
warfarin (target INR, 2.0-3.0) in a double-blind,
double-dummy fashion for a median duration of 1.8
years. The primary safety end point was major bleeding
defined according to the International Society on
Thrombosis and Hemostasis (ISTH) criteria. Key second-
ary end points included whether apixaban provided
superior stroke reduction over warfarin, the incidence of
major and minor bleeding defined by multiple definitions,
the incidence of myocardial infarction, and death from any
cause. Key exclusion criteria were AF due to a reversible
cause, mitral stenosis, concomitant conditions other than AF
that required anticoagulation, an indication for clopidogrel
and aspirin, recent stroke, severe renal insufficiency, or
severe anemia (hemoglobin [Hb] b9.0 g/dL). All national
Figure 1
Association between anemia and the incidence of stroke or systemic embolism. A, Kaplan-Meier analysis of the cumulative incidence of stroke or
systemic embolism according to the presence or absence of anemia at baseline. Anemia was defined according to the WHO criteria (Hb b13.0 g/dL
in men and Hb b12.0 g/dL in women). B, Graphic representation of the HR (95% CI) for stroke or systemic embolism according to baseline Hb levels.
*Adjusted for age, weight, region, diabetes, hypertension, CHADS2 score, at least moderate valvular heart disease, prior stroke or systemic embolism,
type of AF, and prior warfarin use.
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study. All patients provided written informed consent
before entry into the study. This study was sponsored by
Bristol-Myers Squibb and Pfizer, Inc.
Definition of anemia
For the present analysis, we selected patients with Hb
values available at baseline. Anemia was defined
according to the World Health Organization (WHO)
criteria (Hb b13.0 g/dL in men and Hb b12.0 g/dL in
women). Information about Hb during follow-up was
collected every 3 months and was used to define anemia
during follow-up using the same criteria.
Definitions and outcomes
We focused our analysis on the association between
baseline anemia and thromboembolic events or bleed-
ing.17,18 Stroke was defined as a focal neurologic deficit
from a nontraumatic cause lasting at least 24 hours and
was categorized as ischemic, hemorrhagic, or of uncer-
tain type. ISTH major bleeding was defined as clinically
overt bleeding accompanied by 1 or more of the
following: a decrease in Hb levels of at least 2 g/dL,
transfusion of at least 2 U of packed red cells, or bleeding
that is fatal or occurs at a critical site. Clinically relevant
nonmajor bleeding was defined as clinically overt
bleeding that did not satisfy the criteria for major bleeding
and that led to hospital admission, physician-guided
medical or surgical treatment, or a change in antithrom-botic therapy. Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Arteries
(GUSTO) major or moderate bleeding was defined as
clinically relevant bleeding that was intracranial, causing
severe hemodynamic compromise, or required a transfu-
sion. The GUSTOminor bleedingwas defined as clinically
overt bleeding that did not comply with the definition of
GUSTO major or moderate bleeding. Thrombolysis In
Myocardial Infarction (TIMI) major bleeding was
defined as bleeding that was intracranial, causing a cardiac
tamponade, or associated with a drop in Hb of N5 g/dL.
The TIMI minor bleeding was defined as a drop in Hb
between 3 and 5 g/dL with an identified bleeding site or
when spontaneous gross hemoptysis, hematuria, or
hematemesis occurred. Creatinine clearance was estimat-
ed using the Cockroft-Gault formula and stratified as
normal (N80 mL/min per 1.73 m2), moderately impaired
(between 50 and 80 mL/min per 1.73 m2), and severely
impaired (b50 mL/min per 1.73 m2).
Statistical analysis
Continuous baseline variables are summarized as
medians and 25th and 75th percentiles and compared
using the Wilcoxon test. The CHADS2 and HAS-BLED
scores are presented as mean and SD and compared using
t tests. Categorical variables are presented as frequencies
and percentages and compared using χ2 tests. Cumula-
tive event rates according to the presence or absence of
anemia were calculated by the Kaplan-Meier method and
Figure 2
Efficacy and safety end points in patients with and without anemia. Forest plots depicting the adjusted HR (95% CI) for the association between
anemia and thromboembolic events, bleeding complications, or mortality. *Rates per 100 patient-years of follow-up.
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anemia at baseline were identified using a multivariable
logistic regression model. Candidate variables for inclu-
sion in the model were sociodemographic characteris-
tics, medical history, and current medications.
Continuous variables were tested for linearity using
restricted cubic splines and transformed if needed.
Variables included in the final model were selected
using backward selection algorithm with α level to stay in
the model set to .05. The association between anemia or
continuous Hb and the incidence of the different
outcomes was estimated using a Cox regression model
and presented as a hazard ratio (HR) with associated
2-sided 95% CI. Adjusted HRs were derived using a
prespecified set of adjustment variables for each individ-
ual end point. The interaction between anemia and
selected prespecified subgroups (age, sex, CHADS2 and
HAS-BLED scores, history of diabetes, coronary artery
disease, renal insufficiency, warfarin experience, and
history of bleeding) on ISTH major bleeding was
additionally explored. Incidence of new anemia was
based on Hb levels measured postrandomization. An HR
comparing randomized treatments was derived using a
parametric model for interval-censored data and assum-ing a Weibull distribution for the time to new-onset
anemia. To determine whether randomized treatment
influenced the propensity to develop anemia, the
incidence of new-onset anemia was assessed in
warfarin-naive patients. Rates of new-onset anemia by
randomized treatment were estimated using the para-
metric model. All analyses were performed using SAS
version 9.4 (SAS Institute, Inc, Cary, NC).Results
Prevalence of anemia
Of the 18,201 patients randomized in the
ARISTOTLE trial, baseline Hb values were available
at randomization in 18,103 (99.5%) patients. At that
time point, 2,288 (12.5%) patients had anemia
according to the WHO criteria. Baseline demo-
graphics according to the presence or absence of
anemia at randomization are displayed in Table I. In
general, patients with anemia were older; had more
comorbidities; and had more often experienced prior
stroke, systemic embolism, or bleeding events. Both
CHADS2 and HAS-BLED scores were significantly
higher in patients with anemia.
Figure 3
Association between anemia and the incidence of ISTH major bleeding. A, Kaplan-Meier analysis of the cumulative incidence of ISTH major
bleeding according to the presence or absence of anemia at baseline. Anemia was defined according to the WHO criteria (Hb b13.0 g/dL in men
and Hb b12.0 g/dL in women). B, Graphic representation of the HR (95% CI) for ISTH major bleeding according to baseline Hb levels. *Adjusted
for age, CHADS2 score, HAS-BLED score, sex, region, coronary artery disease, history of myocardial infarction, history of bleeding, and renal
function.
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The incidence of stroke or systemic embolism was
comparable between patients with or without baseline
anemia (Figures 1, A, and 2). There was also no
association between Hb considered as a continuous
variable and the incidence of stroke or systemic
embolism (Figure 1, B). Similar results were obtained
when stroke, stroke subtype, or systemic embolism was
considered separately (Figure 2). The presence of anemia
was also not associated with the incidence of future
myocardial infarction (Figure 2).
Anemia, bleeding, and mortality
The presence of anemia at baseline was associated with
a 1.9-fold higher incidence of ISTH major bleeding events
(Figures 2 and 3, A). Every 1-mg/dL drop in Hb was
associated with a 29% increase in the risk of ISTH major
bleeding (Figure 3, B). The association between baseline
anemia and major bleeding was consistent across multiple
bleeding definitions (Figure 2) and several clinically
relevant subgroups (Table II). The association between
anemia and ISTH major bleeding was stronger in men than
in women and also stronger in warfarin-experienced
versus warfarin-naive patients. Furthermore, there was a
trend toward a stronger association between anemia and
bleeding in younger compared with older patients.
Baseline anemia was also associated with a 68% increase
in all-cause mortality (Figures 2 and 4, A). Accordingly,
every 1-mg/dL drop in Hb was associated with a 44%
increase in the hazard of all-cause mortality (Figure 4, B).When this analysis was censored for bleeding reported as
cause of death, the results were similar (adjusted HR,
1.551; 95% CI, 1.337-1.799).
Randomized treatment and anemia
The benefits of apixaban over warfarin for the
prevention of stroke and bleeding were consistent
among patients with and without anemia (Figure 5, A,
and Table III). New anemia developed in approximately
30% of the warfarin-naive patients during follow-up. The
incidence of new-onset anemia was significantly lower in
patients randomized to apixaban compared with those
randomized to warfarin (HR, 0.91; 95% CI, 0.84-0.98; P =
.037) (Figure 5, B).Discussion
Anemia has been associated with a large variety of
adverse outcomes, ranging from cancer to heart failure
hospitalizations.12-16,19,20 The question therefore arises
whether anemia should be considered as a risk factor for
an increased bleeding propensity or rather represents a
nonspecific comorbidity that is common in vulnerable
patients. In patients with AF, anemia has primarily been
considered as a predictor of bleeding,5-11 but recent
evidence suggests that it may also predict stroke.16 In the
current analysis of a large contemporary cohort of
anticoagulated patients with AF, we confirmed that the
presence of anemia is associated with an increased
incidence of future bleeding and mortality. In contrast,
Table II. Association between anemia and ISTH major bleeding in prespecified subgroups.
Anemia No anemia






b65 3.22 (21) 1.19 (105) 2.660 (1.665-4.250) .0726 2.113 (1.291-3.458) .0628
65-75 5.33 (68) 2.04 (216) 2.610 (1.987-3.429) 2.398 (1.809-3.178)
≥75 6.76 (98) 3.77 (277) 1.773 (1.408-2.233) 1.618 (1.276-2.052)
Sex
Male 6.29 (137) 2.15 (378) 2.885 (2.372-3.508) .0060 2.147 (1.747-2.640) .0410
Female 416 (50) 2.39 (220) 1.731 (1.273-2.354) 1.474 (1.077-2.018)
CHADS2 score
1 4.30 (33) 1.68 (169) 2.556 (1.760-3.713) .5256 2.139 (1.459-3.137) .4341
2 5.56 (73) 2.24 (212) 2.472 (1.894-3.225) 2.184 (1.659-2.874)
≥3 6.24 (81) 3.01 (217) 2.031 (1.573-2.622) 1.654 (1.270-2.153)
HAS-BLED score
0-1 3.71 (42) 1.55 (181) 2.377 (1.699-3.326) .8386 1.813 (1.283-2.562) .7606
2 5.22 (68) 2.40 (229) 2.163 (1.649-2.835) 1.915 (1.447-2.533)
≥3 8.15 (77) 3.39 (188) 2.375 (1.822-3.097) 2.163 (1.644-2.846)
Diabetes
Yes 6.66 (72) 2.45 (153) 2.672 (2.018-3.537) .3601 2.323 (1.731-3.117) .2640
No 5.01 (115) 2.17 (445) 2.288 (1.864-2.809) 1.735 (1.403-2.146)
Renal impairment
Severe or moderate 7.24 (73) 4.10 (141) 1.737 (1.309-2.305) .2923 1.604 (1.203-2.138) .4292
Mild 5.77 (81) 2.46 (274) 2.348 (1.832-3.008) 2.139 (1.660-2.755)
No impairment 3.46 (33) 1.49 (180) 2.300 (1.586-3.333) 1.908 (1.305-2.790)
CAD
Yes 5.63 (77) 2.04 (176) 2.740 (2.096-3.582) .3483 2.069 (1.566-2.732) .5957
No 5.47 (110) 2.33 (422) 2.321 (1.881-2.863) 1.868 (1.504-2.320)
Warfarin experience
Naive 4.48 (62) 2.32 (266) 1.891 (1.434-2.494) .0216 1.445 (1.085-1.924) .0120
Experienced 6.26 (125) 2.17 (332) 2.879 (2.343-3.537) 2.267 (1.831-2.807)
History of bleeding
Yes 8.33 (54) 3.13 (131) 2.643 (1.924-3.630) .5121 2.301 (1.655-3.198) .3000
No 4.87 (133) 2.07 (466) 2.335 (1.925-2.831) 1.768 (1.448-2.160)
⁎Rates per 100 patient-years of follow-up.
†Hazard ratio is for anemia versus no anemia.
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stroke or other thromboembolic events. These findings
therefore indicate that anemia does, indeed, primarily
signal an increased bleeding risk and should prompt
measures to prevent bleeding. Treatment with apixaban
resulted in a reduction in the incidence of new anemia,
and apixaban demonstrated similar reductions in stroke
and bleeding compared with warfarin in patients with or
without anemia at baseline. These findings suggest that
apixaban should be preferred over warfarin in patients
with AF regardless of whether or not they have anemia.
Anemia in patients with AF
Although the incidence of anemia was relatively low at
baseline, one-third of the patients without anemia
developed anemia during follow-up. The high incidence
and prognostic significance of anemia underscore the
fact that it is an important comorbidity in patients with
AF that should not be overlooked. Anemia resolved in
most patients, suggesting that it was caused by atransient or reversible etiology such as substrate
deficiency or bleeding. Nevertheless, the strong associ-
ation between anemia and mortality may also point
toward other concomitant chronic diseases such as renal
dysfunction or cancer. Indeed, a recent analysis showed
that anemia was a predictor of new malignancies in
patients with AF.16
Therefore, the association between anemia and bleed-
ing propensity may indicate that anemia is a marker for
occult bleeding or general vascular frailty. Alternatively,
anemia may represent a surrogate for unrelated comor-
bidities that predispose to bleeding events. Unfortunate-
ly, the design of outcome trials such as ARISTOTLE
precludes any meaningful interpretation of the etiology of
anemia or the nature of its association with bleeding
events.
Anemia and stroke
Anemia is common in patients at an increased risk for
stroke, which is underscored by the current analysis
Figure 4
Association between anemia and the incidence of all-cause mortality. A, Kaplan-Meier analysis of the cumulative incidence of stroke or systemic
embolism according to the presence or absence of anemia at baseline. Anemia was defined according to the WHO criteria (Hb b13.0 in men and
Hb b12.0 g/dL in women). B, Graphic representation of the HR (95% CI) for all-cause mortality according to baseline Hb levels. *Adjusted for age,
systolic and diastolic blood pressure, weight, CHADS2 score, sex, region, hypertension, left bundle-branch block, history of myocardial infarction,
prior stroke or systemic embolism, smoking, prior warfarin use, New York Heart Association class, and renal function. *Adjusted event rate was
derived with all covariates set to their mean values.
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baseline anemia. Nevertheless, anemia at baseline was
not associated with an increased risk of stroke or systemic
embolism. Our findings are in contrast with a recent
analysis of the RE-LY trial, where anemia was associated
with an increased risk of stroke.16 This may appear
contradictory because the inclusion criteria and end
points of both trials were very similar.17,21 However, the
association between baseline anemia and bleeding in the
RE-LY trial was much stronger than the association
between anemia and stroke. Although our analysis cannot
exclude that anemia and stroke risk are related, it does
underscore the fact that anemia is more strongly
associated with bleeding than with stroke.
Anemia and bleeding
Oral anticoagulants produce a net clinical benefit in
patients at risk for stroke, irrespective of their risk of
bleeding.22-25 Accordingly, guidelines advocate OACs in
all patients at risk for stroke.26 To prevent potentially fatal
bleeding events, it is therefore essential to closely
monitor patients with a high bleeding risk. However,
bleeding risk is generally underestimated by clinicians,27
and the predictive accuracy of contemporary risk scores
is modest.5,28 There is also considerable overlap between
the components of contemporary bleeding risk calcula-
tors and stroke prediction algorithms. It would therefore
be particularly instrumental to construct algorithms that
can differentiate stroke risk from bleeding propensity. In
our analysis, the strong and specific association betweenanemia and bleeding reinforces the notion that anemia
should be included in such bleeding risk algorithms.7,8
Indeed, the addition of Hb and other biomarkers to
established clinical predictors in the age, biomarkers, and
clinical history risk calculator resulted in superior
bleeding risk assessment with only minimal overlap
with predictors for stroke.29
Clinical implications
The presence of anemia should prompt a detailed
diagnostic assessment of the etiology focused on
reversible causes. In addition, other reversible factors
that may precipitate bleeding such as concomitant
antiplatelet or anti-inflammatory drugs, alcohol intake,
or uncontrolled hypertension should be addressed.21
Apixaban reduces the risk for stroke and major bleeding
when compared with warfarin, and the current analysis
indicates that similar benefits may be expected in patients
with anemia.17 The development of new anemia was also
less common in patients randomized to apixaban.
Because apixaban reduced the incidence of bleeding, it
is tempting to speculate that new-onset anemia reflects
differences in recent occult or clinical bleeding events.
Unfortunately, the data available in ARISTOTLE preclude
any meaningful investigation of the etiology of anemia
and cannot provide any temporal associations with prior
bleeding. Of the other non–vitamin K antagonist OACs
that are currently available, low-dose dabigatran also
reduced bleeding compared with warfarin and may be
considered in these patients as well; however, low-dose
Figure 5
Effect of randomized treatment on the association between anemia and ISTH major bleeding and on the incidence of new anemia. A, Kaplan-
Meier analysis of the cumulative incidence of ISTH major bleeding according to anemia status at baseline and randomized treatment. Anemia was
defined according to the WHO criteria (Hb b13.0 g/dL in men and Hb b12.0 g/dL in women). B, New-onset anemia by randomized treatment in
warfarin-naive patients. Lines represent HRs for new anemia derived using a parametric model for interval-censored data and assuming a Weibull
distribution for the time to new-onset anemia.
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anemia.16,21
Limitations
This analysis is from a large data set and includes
extensive multivariable adjustments. It is, however, a post
hoc analysis, and the potential for confounding remains
despite extensive multivariable adjustments. Patients
with baseline Hb levels b9 g/dL were excluded from
the trial, and the analysis was performed in a population
selected according to the ARISTOTLE inclusion criteria.
The actual incidence, severity, and prognostic signifi-
cance of anemia may be different in the general
community. The current analysis was also not designed
to determine the etiology of anemia.Conclusions
Anemia is associated with a higher incidence of
bleeding and mortality, but not of stroke, in antic-
oagulated patients with AF. Apixaban has similar benefits
over warfarin among patients with and without anemia.
Apixaban is therefore an attractive anticoagulant for
stroke prevention in patients with AF irrespective of the
presence of anemia.
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Table III. Interaction between anemia and randomized treatment












Stroke or SE 1.13 (22) 2.00 (40) 0.564 (0.335-0.949) 1.28 (188) 1.55 (224) 0.829 (0.683-1.006) .1692
All-cause mortality 7.51 (151) 7.21 (148) 1.045 (0.833-1.311) 2.99 (448) 3.46 (514) 0.863 (0.760-0.979) .1503
MI 1.07 (21) 1.05 (21) 1.026 (0.560-1.878) 0.47 (69) 0.55 (81) 0.842 (0.611-1.161) .5744
Safety end points
ISTH major bleeding 4.75 (80) 6.32 (107) 0.750 (0.561-1.002) 1.81 (246) 2.67 (352) 0.681 (0.578-0.801) .5659
GUSTO seve r e o r
moderate bleeding
3.06 (52) 5.28 (90) 0.578 (0.411-0.813) 1.07 (146) 1.76 (234) 0.608 (0.494-0.747) .8058
TIMI major bleeding 1.28 (22) 3.30 (57) 0.387 (0.236-0.633) 0.91 (125) 1.49 (198) 0.615 (0.492-0.770) .0938
Any bleeding 26.87 (367) 35.24 (463) 0.769 (0.671-0.882) 17.09 (1980) 24.59 (2577) 0.709 (0.669-0.752) .2941
MI, myocardial infarction.
⁎Rates per 100 patient-years of follow-up.
†Hazard ratio is for apixaban versus warfarin.
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